Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 674 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Edema Clear all
Not listed Not applicable Interventional

Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema

NCT03866005
View directory record Official record
Conditions
Center-involved Diabetic Macular Edema (CI-DME)
Interventions
Diabetes Visual Function Study (DiVFuSS) softgels, canola oil placebo softgels, 2 per day
Dietary Supplement · Other
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Olympia, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 29, 2026, 4:07 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Prenatal Steroids for Treatment of Congenital Cystic Adenomatoid Malformations (CCAM)

NCT00670956
View directory record Official record
Conditions
Congenital Cystic Adenomatoid Malformation
Interventions
Betamethasone, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 29, 2026, 4:07 PM EDT
Terminated Not applicable Interventional

Acupuncture and Post-Surgical Wound Healing

NCT00260494
View directory record Official record
Conditions
Postoperative Complications, Surgical Wound Infection, Surgical Wound Dehiscence
Interventions
acupuncture, sham acupuncture
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Oct 29, 2026, 4:07 PM EDT
Terminated Phase 4 Interventional

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

NCT04563299
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 29, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Results available

B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial

NCT03136198
View directory record Official record
Conditions
Heart Failure, Heart Failure Acute, Acute Cardiac Pulmonary Edema, Acute Cardiac Failure
Interventions
LUS-guided strategy-of-care, Usual Care, Intravenous Loop Diuretic, Vasodilator, Non invasive Ventilation (NIV)
Other · Drug · Device
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Indianapolis, Indiana • Detroit, Michigan • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 29, 2026, 4:07 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)

NCT01769352
View directory record Official record
Conditions
Post-surgical Cystoid Macular Edema (PSCME)
Interventions
PredA + Kelac
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 29, 2026, 4:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin

NCT02630303
View directory record Official record
Conditions
Fibrosis, Scarring, Scar, Wounds, Injuries, Keloid, Cicatrix, Hypertrophic
Interventions
LED-RL Phototherapy, Mock Therapy
Device
Lead sponsor
Jared Jagdeo, MD, MS
Federal
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 29, 2026, 4:07 PM EDT
Terminated Phase 1Phase 2 Interventional

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema

NCT00358423
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Pegaptanib Sodium, Control
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2008 · Synced Oct 29, 2026, 4:07 PM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02980874
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 29, 2026, 4:07 PM EDT
Withdrawn Phase 1 Interventional

Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study

NCT00676559
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Efalizumab, Ranibizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Tucson, Arizona • San Diego, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 29, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Results available

REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study

NCT01247220
View directory record Official record
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Ranibizumab, Peripheral Laser
Drug · Procedure
Lead sponsor
Retina Associates of Florida, P.A.
Other
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Oct 29, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

NCT00168324
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
700 µg Dexamethasone, 350 µg Dexamethasone, Sham Injection
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 29, 2026, 4:07 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

NCT00605280
View directory record Official record
Conditions
Macular Edema Associated With Diabetes Mellitus
Interventions
Standard of Care, Macugen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 29, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT02724644
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, Placebo Comparator
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
16
States / cities
Beverly Hills, California • Murrieta, California • Oceanside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 29, 2026, 4:07 PM EDT
Withdrawn Phase 2 Interventional

Ranibizumab as a Rescue Therapy for Diabetic Macular Edema

NCT01253694
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
injection of 0.5 mg of Intravitreal Ranibizumab
Drug
Lead sponsor
New England Retina Associates
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Norwich, Connecticut
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 29, 2026, 4:07 PM EDT
Completed Phase 1 Interventional

Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

NCT01997164
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions
REGN910-3, REGN910, Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Beverly Hills, California • Winter Haven, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 29, 2026, 4:07 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF

NCT01946399
View directory record Official record
Conditions
Retinal Vein Occlusion (RVO), Macular Edema
Interventions
Ozurdex implant
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 29, 2026, 4:07 PM EDT
Terminated Not applicable Interventional Results available

Compression Wraps as Adjuvant Therapy in Management of Acute Systolic Heart Failure

NCT04095416
View directory record Official record
Conditions
Heart Failure; With Decompensation
Interventions
ACE compression wrap
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 29, 2026, 4:07 PM EDT
Completed No phase listed Observational

Computer Detection of Diabetic Retinopathy Compared to Clinical Examination

NCT01625598
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Photography of the retina, Retinal photography
Procedure
Lead sponsor
Digital Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Mesa, Arizona • Phoenix, Arizona • Cedar Rapids, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Oct 29, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Results available

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03093701
View directory record Official record
Conditions
Retinal Vein Occlusion, Macula Edema
Interventions
TLC399 (ProDex)
Drug
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 29, 2026, 4:07 PM EDT
Completed Early Phase 1 Interventional

Photobiomodulation for the Treatment of Diabetic Macular Edema

NCT02457975
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
670nm PBM, intravitreous VEGF-inhibitors
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 29, 2026, 4:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Open-label, Non Significant Risk, Adhesive Wear Validation Study for the On Body Drug Delivery Device Component of the SQIN-01 Furosemide Infusor (Infusor Device)

NCT04836572
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
3M 1529 Adhesive Tape
Other
Lead sponsor
SQ Innovation, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 29, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03917472
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 29, 2026, 4:07 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

NCT04527107
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3, THR-149 0.13mg, THR-149 0.13mg + aflibercept 2mg, aflibercept 2mg + THR-149 0.13mg, Aflibercept 2mg
Drug
Lead sponsor
Oxurion
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 29, 2026, 4:07 PM EDT